Evidence map›Paper›PMID 40190807›Full record

ArticleDrug design, development and therapy2025

Design, Synthesis, and Biological Evaluation of Novel Hydroxytyrosol Derivatives as Protectors for Vascular Endothelium Against Lipid Overload.

Xi-Xi Hou, Shuang Wang, Xiao-Xia Ma, Ying Wen, Zhi-Jun Li, Xu-Yun Liu, Xing Zhang, Yang Zhang, Xiang-Yang Qin

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xi-Xi Hou *College of Life Sciences, Northwest University, Xi'an, People's Republic of China.
Shuang Wang *College of Life Sciences, Northwest University, Xi'an, People's Republic of China.
Xiao-Xia Ma *College of Life Sciences, Northwest University, Xi'an, People's Republic of China.
Ying Wen *College of Life Sciences, Northwest University, Xi'an, People's Republic of China.
Zhi-Jun LiSchool of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi'an, People's Republic of China.
Xu-Yun LiuCenter for Mitochondrial Biology and Medicine, the Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiao Tong University, Xi'an, People's Republic of China.
Xing ZhangDepartment of Recuperation and rehabilitation for flight personnel, School of aerospace medicine, fourth Military Medical University, Xi'an, People's Republic of China.
Yang ZhangDepartment of Medical Electronics, School of Biomedical Engineering, Fourth Military Medical University, Xi'an, People's Republic of China.ORCID 0000-0002-8540-1254
Xiang-Yang QinDepartment of Chemistry, School of Pharmacy, Fourth Military Medical University, Xi'an, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: Hydroxytyrosol (HT) is reported to protect endothelial cells against metabolic overload through inhibiting inflammation. However, the hydrophilic nature of HT limits its oral bioavailability and biological efficiency. The aim of the study was to design and synthesize novel hybrid molecules to improve HT's biological efficiency. Materials and Methods: A pharmacophore connection strategy was used to design and synthesize novel hybrid molecules by combining HT or its analogues with adamantane (ADM). Palmitic acid (PA) was used to induce lipid overload in HAEC cells, and P407 was used to induce acute hyperlipidemia in C57 mice. Results: We found that DP-ADM, combining ADM and dopamine (a HT analogues), exhibited potent protective effects against metabolic overload-induced endothelial dysfunction. DP-ADM showed low toxicity and inhibited inflammation in response to PA overload in cultured endothelial cells. Additionally, it (30 mg/kg) decreased circulating lipids to an extent similar to HT in a mouse model of hyperlipidemia and was superior to HT in decreasing circulating inflammatory cytokine. It was also superior to HT in improving vascular endothelial function in mice with hyperlipidemia. Mechanistically, DP-ADM inactivated MAPK signaling, as evidenced by downregulated phosphorylation of p38 and Erk. Inhibition of MAPK or NF-κB abolished the anti-inflammatory effect of DP-ADM. Specifically, DP-ADM activated FoxO1 signaling and increased mitochondrial biogenesis in endothelial cells. Conclusion: Overall, DP-ADM is a superior form of HT, highlighting its potential therapeutic use in improving endothelial function in metabolic diseases.

Indexed as

Drug DesignEndothelium, VascularHyperlipidemiasPhenylethyl AlcoholAnimalsCells, CulturedDose-Response Relationship, DrugHumansLipidsMaleMiceMice, Inbred C57BLMolecular StructurePalmitic AcidStructure-Activity Relationship3,4-dihydroxyphenylethanolLipidsPalmitic AcidPhenylethyl Alcoholendothelial functionhydroxytyrosol derivativesinflammationlipid overloadMAPK

Identifiers

PMID40190807
PMCPMC11971996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.